Hybrid Molecules Combining GABA-A and Serotonin 5-HT6 Receptors Activity Designed to Tackle Neuroinflammation Associated with Depression




Marcinkowska, M., Mordyl, B., Fajkis-Zajaczkowska, N., Siwek, A., Karcz, T., Gawalska, A., Bucki, A., Żmudzki, P., Partyka, A., Jastrzębska-Więsek, M., Pomierny, B., Walczak, M., Smolik, M., Pytka, K., Mika, K., Kotańska, M., & Kolaczkowski, M. (2023). Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression. European Journal of Medicinal Chemistry, 141267.



There is clear evidence that the presence of inflammatory factors and impaired GABA-ergic Journal Pre-proof neurotransmission in depressed patients is associated with poor clinical outcome. We designed hybrid molecules, bearing the GABA molecule assembled with chemical fragments that interact with the serotonin 5-HT6 receptor. Such a combination aimed to curb neuroinflammation, remodel GABA-ergic signaling, and provide antidepressant-like activity. The most promising hybrid 3B exerted nanomolar affinity for 5-HT6 receptors and exerted agonistic properties on GABA-A receptors. Developability studies conferred that 3B exerted favorable drug-like properties and optimal brain penetration. In in vivo studies, 3B exerted robust antidepressant-like activity and proved to be highly effective in reducing levels of oxidative stress markers and the pro-inflammatory cytokine IL-6. The inetersting pharmacological profile of 3B makes it a promising candidate for further development for depression associated with neuroinflammation.

Go to journal

Get in Touch

We strive to provide the best for our customers, and we are always ready to help. Please let us know if you have a question for us.

Follow us